Medtech acquires Percogesic from Roche-Syntex, plans television campaign.
This article was originally published in The Tan Sheet
Executive Summary
MEDTECH ACQUIRES PERCOGESIC U.S. MARKETING RIGHTS FROM ROCHE-SYNTEX, the Jackson Hole, Wyo.- based marketer announced Jan. 2. The addition of the analgesic to the Medtech stable along with recent purchases from American Home Products is expected to boost annual sales "more than $40 mil." in 1997. Roche-Syntex acquired Percogesic, along with Aleve, from Procter & Gamble in June ("The Tan Sheet" July 1, 1996, p. 1). The pain reliever/fever reducer contains 325 mg acetaminophen and 30 mg phenyltoloxamine citrate.